Protection and Safety of rabies vaccine when administered intradermally
- Conditions
- Health Condition 1: null- Dog bite victims
- Registration Number
- CTRI/2012/06/002720
- Lead Sponsor
- I
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 70
Subjects with low risk Category II and Category III exposures.
Subjects willing to give signed informed consent.
Subjects willing to give blood samples on recommended days.
Subjects available for minimum of 6 months follow-up.
Dog/Cat domesticated, available for 10 days observation, apparently healthy, provoked bite, wound washed with soap and water and consulting for vaccination within 48 hours of exposure.
Pregnancy & lactation.
Subjects who had received any type of rabies vaccine/immunoglobulin in the past.
Subjects with very severe bite wounds.
Subjects with chronic illness or cancers.
Subjects on steroids or any other immunosuppressant or is known to be HIV positive.
Subjects planning for surgery in the next 3 month
Subjects on concomitant antimalarials.
Subjects with history of allergy to any ingredient of the vaccine.
Participation in another clinical trial in the past 3 months.
Past history of chronic alcoholic abuse.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Immunogenicity of new indigenously produced purified chick embryo cell rabies vaccine when administered intradermallyTimepoint: Rabies Virus Neutralising Antibody estimation on Days 14, 28,90 & 180
- Secondary Outcome Measures
Name Time Method Safety of new indigenously produced purified chick embryo cell rabies vaccineTimepoint: Days 0,3,7,14 & 28